Fluidda
is all about understanding lung pathology and physiology
Dr. Jan De Backer
CEO FLUIDDA
BREATHE THE AIR!
With one person dying every minute from a respiratory condition, patients with pulmonary diseases deserve better, faster and less costly treatments. At Fluidda, we are leading the way in a world where the quality of air is under stress.
Our aim is to optimize treatment pathways, reduce healthcare costs, bring therapies to the market faster and move toward value-based healthcare. Our FRI technology will help patients worldwide to breathe the air!
Fluidda’s 2nd Research And Findings Magazine
Discover all the latest research and FRI applications by entering your e-mail address below and we will send you this Magazine for free. The following topics are covered in the first edition of our magazine:
- How to predict course of COVID-19
- Solving the mystery of long COVID
- Early and rapid detection of lung diseases
- FRI in the transition from research to clinical practice
Send download link to:
Are you a Healthcare company?
Fluidda can speed up your respiratory drug development or medical device development and derisk clinical trials.
Broncholab
Learn how Fluidda assists radiologists and pulmonologists with treatment optimization for respiratory patients. Fluidda offers respiratory solutions to optimize the treatment of your patient
FRI enables you to look inside the lung, by adding visualization and regional information to these measurements, therefore providing further insight into the regional functionality of the lung.
In clinical practice, physicians have to deal with an unmet need for improvement of current diagnostic tools. For personalized and precision treatment, an improved understanding of disease pathophysiology and complexity can be helpful in choosing the most suitable treatment approach. Especially in the difficult cases, it is essential to define the correct approach. Currently, this results in high healthcare costs for chronically ill patients.
Recent News >
Fluidda helps Firefighters
Californian firefighters are exposed to repeated, intense wildfire smoke, and the long term effects are still unknown. FiGHT is a non-profit charity campaign aiming at screening firefighters and first responders for lung diseases that might be present but are not yet reflected in standard of care (spirometry) or symptoms.
Fluidda’s Functional Respiratory Imaging technology combined with artificial intelligence allows patient-specific treatment to be assigned. Discover how Fluidda supports firefighters on https://www.jointhefight.info/